Introduction {#sec0001}
============

Migraine headache is a global phenomenon and affects more than 10% of the world\'s population.[@bib0001] It is the most common brain disorder and is characterised by moderate to severe unilateral headache that may be accompanied by vomiting, nausea, photophobia and phonophobia.[@bib0001], [@bib0002] It is more common than both diabetes mellitus and asthma.[@bib0003], [@bib0004] Women are more than twice as likely to suffer with migraine than men, and it is more common in students and urban residents.[@bib0001] Approximately one third of migraine sufferers are not helped by standard therapies.[@bib0005], [@bib0006] The economic effect of migraine is significant, surpassing \$13 billion per year in the United States alone, predominantly through the cost of medicines and time off work.[@bib0007]

Patients experiencing headache on more than 15 days per month -- where at least eight of these headache days meet the criteria for migraine or respond to migraine-specific therapy -- may be diagnosed with chronic migraine.[@bib0008] It is estimated that between 1.3% and 2.4% of the general population suffers from chronic migraine and its additional socioeconomic and disability sequelae.[@bib0009], [@bib0010], [@bib0011], [@bib0012]

A cohort of chronic migraine patients responded to a botulinum toxin type A injection administered into specific anatomic extra-cranial locations. In the standard paradigm, the majority of these injection sites are agnostic to the specific headache location in any one patient -- although up to eight further injections may then be given using a 'follow the pain' strategy. The PREEMPT studies provide evidence supporting the effectiveness of both botulinum toxin and placebo injections for chronic migraine, with greater improvement in the intervention group, in terms of headache days per month and improved health-related quality of life.[@bib0013], [@bib0014], [@bib0015], [@bib0016]

The extra-cranial migraine trigger site concept differs from traditional concepts of migraine pathogenesis, in that it describes the mechanical compression of an extra-cranial peripheral nerve by localised muscle activity, which usually corresponds to the area of onset of the headache. Numerous extra-cranial trigger sites have been described in the literature around the cranio-facial regions, posterior head and neck and nose.[@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021] Consistent aberrant peripheral signalling through intermittent nerve compression is thought to initiate centrally mediated migraine activity.[@bib0022], [@bib0023] Botulinum toxin injections at extra-cranial trigger sites cause paralysis of the surrounding muscle tissue and hence temporarily de-activate that specific trigger site. It is associated with low complication rates, but it can only provide temporary relief.[@bib0013] Patients with chronic migraine responsive to botulinum toxin at certain trigger sites may therefore be candidates for surgical intervention -- especially if botulinum toxin therapy becomes less effective over time or is associated with unwanted side effects.

A variety of surgical options for chronic migraine have been proposed, including peripheral nerve decompression by myectomy or foraminotomy, nerve excision, artery resection and/or nasal surgery. The premise of surgical deactivation of trigger sites through these methods is to ameliorate migraine symptoms and achieve permanent deactivation of the trigger site.[@bib0017]^,^[@bib0024], [@bib0025], [@bib0026]

Rationale {#sec0002}
---------

The effectiveness of surgical intervention for chronic migraine has been asserted by a number of primary clinical studies.[@bib0026], [@bib0027], [@bib0028], [@bib0029] However, to date, there has been no critical evaluation of the quality of the evidence for migraine surgery or whether the available evidence supports its effectiveness. Furthermore, the risk of adverse events is unclear. This systematic review of surgical interventions for chronic migraine provides an objective assessment of the evidence and a descriptive analysis of its effectiveness and adverse outcome rates.

Objectives {#sec0003}
----------

1.To evaluate the quality of evidence for the efficacy of surgical intervention for chronic migraine.2.To determine the effect of surgical intervention on migraine intensity, frequency, duration and migraine headache index (MHI) outcomes through pooled descriptive analysis.3.To determine the risk of adverse events and migraine recurrence following surgical intervention for chronic migraine.

Methods {#sec0004}
=======

The objective of this review was to assess the literature on surgical intervention for migraine with a focus on identifying and evaluating outcome measures and adverse events in accordance using the methodology described in the Cochrane Handbook of Systematic Reviews of Interventions, where applicable.[@bib0030] This review has been performed in accordance with the PRISMA statement.[@bib0031] A comprehensive review protocol was prospectively registered on the PROSPERO database (CRD42017068577).

Search methods {#sec0005}
--------------

Studies were identified thorough a systematic literature search of all records in Ovid MEDLINE and Ovid EMBASE from database inception to June 2017. The primary author (JCRW) completed both 'free-text term' and 'MeSH term' searches by combining variations of the keywords 'migraine' and 'surgery' using Boolean operators.[@bib0020] Only English language articles were considered. The search results were merged, and duplicate citations were discarded. Titles and abstracts were screened in duplicate, and studies unrelated to the research objective were discarded. The full text of each shortlisted paper was read in full by each author independently to assess its eligibility for inclusion. The final list of included studies was compared and discussed between all authors. The bibliographies of included papers and previous reviews were examined to ensure all relevant studies had been considered. Any disparities regarding inclusion of articles were resolved by consensus with reference to the pre-specified inclusion criteria. Published data from included studies were scrutinised for reporting of outcomes. If relevant data were not available for extraction, authors were contacted by email with a specific data request.

Criteria for selecting studies {#sec0006}
------------------------------

Study selection criteria were defined during the protocol stage and included all clinical studies of surgical intervention for chronic migraine. Two authors (JCRW and JL) used a pre-specified, bespoke inclusion/exclusion Excel sheet to independently assess eligibility of studies. Case reports, letters, editorials, anatomical studies and literature reviews were excluded. Study participants were adults undergoing surgical intervention for chronic migraine, diagnosed according to the International Classification of Headache Disorders (ICHD) criteria or International Headache Society (IHS) guidelines where possible.[@bib0032], [@bib0033] Studies of patients with headache other than migraine (including familial hemiplegic migraine, supraorbital rim syndrome and cluster headache) were excluded. Studies were included if they reported on any outcomes following surgery for migraine surgery, including operative outcomes, patient-reported outcomes, recurrence rates and adverse outcomes. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.[@bib0034]

Data extraction {#sec0007}
---------------

Data collection and analysis were performed in accordance with the Cochrane Handbook of Systematic Reviews of Interventions where applicable.[@bib0030] Data were extracted onto a pre-designed electronic form and included location of study, study design, sample size, age of participants, medical comorbidity, migraine characteristics, presence of aura and length of post-operative follow-up. Outcome data were extracted for migraine-specific outcomes, composite headache scores, patient-related outcomes, migraine recurrence and adverse events. Our primary outcome was reduction in migraine severity, based on continuous interval outcome measures and assessed on a visual analogue scale. Secondary outcomes included migraine frequency, migraine duration and composite headache index scores, as well as adverse event and recurrence rates. Two authors (JCRW and JL) extracted the data in duplicate and independently checked the data set for accuracy.

Statistical analysis {#sec0008}
--------------------

We performed simple descriptive statistics for patient demographics. We used a narrative synthesis to summarise the identified surgical and patient-related outcomes with reference to variations in outcome definitions. Pooled rates were calculated for outcomes described by three or more studies to give overall descriptive estimates of effects of surgery and adverse events. Formal meta-analysis was not undertaken because of poor reporting of baseline data, intervention heterogeneity and inconsistent outcome reporting.

Results {#sec0009}
=======

Search strategy {#sec0010}
---------------

Our search strategy identified a total of 789 research articles, 97 of which were potentially relevant to the research question. Of these 97 articles, 46 were read in full and 25 were deemed eligible for inclusion.[@bib0019], [@bib0024], [@bib0025]^,^[@bib0027], [@bib0028], [@bib0029]^,^[@bib0035], [@bib0036], [@bib0037], [@bib0038], [@bib0039], [@bib0040], [@bib0041], [@bib0042], [@bib0043], [@bib0044], [@bib0045], [@bib0046], [@bib0047], [@bib0048], [@bib0049], [@bib0050], [@bib0051], [@bib0052], [@bib0053] Data were immediately available for extraction from 18 study reports.[@bib0019], [@bib0024], [@bib0025]^,^[@bib0027], [@bib0028], [@bib0029]^,^[@bib0042], [@bib0043], [@bib0044], [@bib0045], [@bib0046], [@bib0047], [@bib0048], [@bib0049], [@bib0050], [@bib0051], [@bib0052], [@bib0053] The authors of the remaining seven studies were contacted with additional requests including, as a minimum, baseline demographic data and absolute pre- and post-operative migraine headache variables.[@bib0035], [@bib0036], [@bib0037], [@bib0038], [@bib0039], [@bib0040], [@bib0041] None of the authors were able to provide these data; these studies were excluded and data were extracted from the remaining 18 studies ([Figure 1](#fig0001){ref-type="fig"}, [Table 1](#tbl0001){ref-type="table"}). Details of the excluded studies are shown in Supplementary [Table 1](#tbl0001){ref-type="table"}. In total, 18 study reports were included from 17 distinct primary studies.Figure 1PRISMA flowchart of study attrition.Figure 1.Table 1Characteristics of included studies.Table 1![](fx1a.gif)![](fx1b.gif)

Study characteristics {#sec0011}
---------------------

The included studies were published between 1962 and 2017. Twelve studies were from research groups in the USA, four from Europe (UK, Italy, Greece and Austria), one from Taiwan and one from Iran. Thirteen of the studies were published in plastic surgery journals, two in craniofacial/maxillofacial journals, one in a neurology journal and two in general journals. The median sample size was 35, with a range of 9--229 participants. Fourteen studies were retrospective observational case series and three were prospective RCTs, one of which published two reports of the same trial, one containing data at one-year follow-up and one at five-year follow-up.[@bib0021], [@bib0023] The follow-up periods were not reported in five included studies. In the other studies, the follow-up periods ranged from 6 months to 5 years but were most commonly 12 months or longer.

Across all studies, the median age was 44 years (range 35--51 years) with a female preponderance in all but one study.[@bib0024] Nine of the included studies reported using an established diagnostic classification system for migraine: six used IHS guidelines and three used a specific ICHD classification ([Table 2](#tbl0002){ref-type="table"}).Table 2Diagnostic criteria.Table 2Primary author & yearDiagnostic criteria[\*](#tb2fn1){ref-type="table-fn"}Length of migraine history (months, SD/range)Pre-operative migraine trigger point identificationClinician[⁎⁎](#tb2fn2){ref-type="table-fn"}No. of trigger sites[⁎⁎⁎](#tb2fn3){ref-type="table-fn"}ClinicalImagingInterventionalKnight 1962--152 (108)Clinical------1--2 (U/L)Rapidis 1976--48 (31)Clinical--LA--1 (U/L)Behin 2004ICDH1132 (3--480)ClinicalCTLAENT3--6 (U/L)Dirnberger 2004IHS----------1 (B/L)Poggi 2008IHS--Clinical--BotoxNeurologist1--4 (U/L)Ducic 2009IHS204 (111)Clinical--Botox/LANeurologist1--2 (B/L)Guyuron 2005IHS--Clinical--BotoxNeurologist1--4 (B/L)Guyuron 2011Janis 2011IHS--Clinical--Botox--1--4 (B/L)Chepla 2012----Clinical------1--4 (B/L)Chmielewski 2013----Clinical------1--4 (B/L)Lee 2013----Clinical------1--4 (B/L)Gferer 2014----Clinical--BotoxNeurologist1--3 (B/L)Guyuron 2015ICDH2--Clinical--BotoxNeurologist1 (B/L)Lin 2015--\>120Clinical------1 (B/L)Edoardo 2015ICDH2--Clinical----Neurologist1 (B/L)Omranifard 2016IHS--ClinicalCTBotoxNeurologist1--4 (B/L)Ascha 2017----Clinical--BotoxNeurologist1--4 (B/L)[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12]

The remaining eight studies did not report on whether the diagnosis of migraine was made with reference to any diagnostic criteria. The clinician making a diagnosis of migraine was specified in 10 studies: in nine of these, this was a board-certified neurologist, and in the remaining one study, this was an ear, nose and throat surgeon. One study did not report on how the diagnosis of migraine was made.[@bib0046] Only five studies reported on the pre-intervention length of migraine history, which ranged from 48 to 204 months. Only six studies reported on pre-intervention medication usage.

Trigger point identification methods varied between studies. Five studies used clinical assessment in isolation to guide operative site selection. History and examination findings were further investigated by a trial of local anaesthetic or botulinum toxin injections in 11 studies and adjunct computed tomography imaging in two.

Interventions {#sec0012}
-------------

A number of trigger sites were identified and operated on across the included studies. Four studies evaluated unilateral trigger site deactivation only; the remaining 13 studies surgically deactivated identified trigger sites bilaterally. This appears to be a more recent trend, as no studies since 2009 have used a unilateral approach ([Table 2](#tbl0002){ref-type="table"}). Five studies evaluated a single trigger site, whereas 12 performed between 1 and 6 trigger site deactivations synchronously.

Surgical interventions were extremely heterogeneous both within studies and between studies ([Table 1](#tbl0001){ref-type="table"}). Only six of the studies evaluated a single surgical intervention; the other studies involved more complex surgical interventions, with some including up to six different procedures in the treatment group. In these studies, each patient received a different overall intervention consisting of multiple synchronous procedures. Four studies focussed solely on extracranial peripheral nerves, with interventions directed at the superior cervical sympathetic chain, the zygomaticotemporal nerve, the auriculotemporal nerve and the greater and lesser occipital nerves. Two studies looked solely at resection of the glabellar muscle group in isolation. One study evaluated the effect of excision of the superficial temporal artery in isolation. The remaining studies involved, in various combinations, surgical interventions directed at nerves, arteries, muscle groups and nasal structures. Surgery on nasal structures typically involved a combination of selective turbinectomy and/or septoplasty. One study included additional sinus surgery (in this case, ethmoidectomy and maxillary antrostomy). The three RCT study populations each had different intervention and control groups; therefore, the data could not be synthesised in a meta-analysis.

GRADE assessment {#sec0013}
----------------

All included studies were evaluated against the validated Grading of Recommendations, Assessment, Development and Evaluations (GRADE) standards.[@bib0034] A summary of the quality of evidence for each study, with reasons, is detailed in [Table 3](#tbl0003){ref-type="table"}.Table 3GRADE criteria.Table 3Primary author & yearStudy designMethodological limitationsGrade scoreKnight 1962Observational - RetrospectiveVery small study size no statistical data migraine diagnosis unclear no description of surgical methods variable surgical intervention variable length of follow-up subjective outcome assessment no adverse outcome reportingVery lowRapidis 1976Observational - RetrospectiveVery small study size no statistical data migraine diagnosis unclear subjective outcome assessment no adverse outcome reportingVery lowBehin 2004Observational - RetrospectiveMigraine diagnosis unclear unclear patient enrolment non-validated outcome measures loss to follow-up no adverse outcome reportingVery lowDirnberger 2004Observational - RetrospectiveLeading outcome measure questions post-hoc sub-group analysis selective outcome reporting non-validated outcome measures incomplete reporting of absolute data inadequate length of follow-up no adverse outcome reportingVery lowPoggi 2008Observational - RetrospectiveSmall study size non-validated outcome measures inadequate methodological detail variable surgical intervention risk of participant recall biasVery lowDucic 2009Observational - RetrospectiveMigraine diagnosis unclear variable surgical interventionLowGuyuron 2005\
Guyuron 2011RCTRandomisation not described no power calculation unspecified control group medical therapy loss to follow-up selective participant exclusion from statistical analysis significant improvements in control group (regression to the mean)LowJanis 2011Observational - RetrospectiveSmall study size selective patient enrolment loss to follow-up non-validated outcome measuresVery lowChepla 2012Observational - RetrospectiveVariable anatomy between control and treatment groups unspecified method for control group inclusion no adverse outcome reportingLowChmielewski 2013Observational - RetrospectiveUnbalanced baseline migraine symptoms unspecified method for control group inclusion heterogeneous results multiple retrospective analyses no adverse outcome reportingVery lowLee 2013Observational - RetrospectiveSelective outcome reporting no adverse outcome reportingLowGferer 2014Observational - RetrospectiveSmall study size selective outcome reporting inclusion of re-interventions in statistical analysis conflicting results compared with external study controlLowGuyuron 2015RCTSelective patient enrolment outcomes analysed per site rather than per patient unclear application of statistical testsLowLin 2015Observational - RetrospectiveSmall study size unclear patient enrolment sparse data inadequate length of follow-up inadequate description of diagnostic work-up no adverse outcome reportingVery lowEdoardo 2015Observational - RetrospectiveSmall study size sparse data unclear migraine diagnosis - variable headache syndromes loss to follow-up selective outcome reporting statistical comparison to unrelated studyVery lowOmranifard 2016RCTSmall study size no power calculation unclear patient enrolment randomisation not described unblinded results significant improvements in control group (regression to the mean)LowAscha 2017Observational - RetrospectiveUnclear patient enrolment loss to follow-up variable pre-operative work up lack of site-specific dataLow

The overwhelming majority of the literature on migraine surgery is based upon 'low'- or 'very low'-quality observational data. Owing to a paucity of high quality evidence, no studies were excluded from the data set following GRADE assessment.

Most observational studies were based on small cohorts of patients undergoing surgical intervention for migraine in a single centre. Although these studies typically report similar improvements in the outcome measures assessed, their conclusions are limited by small sample sizes without evidence of preparatory power calculation, unclear enrolment methods, variability in the surgical intervention offered and poor follow-up ([Table 3](#tbl0003){ref-type="table"}). In a number of studies, the diagnostic criteria for migraine are not specified.[@bib0024], [@bib0029], [@bib0042], [@bib0044], [@bib0045], [@bib0049], [@bib0050], [@bib0053] Without a clearly defined patient population, these studies have limited generalisability and do not explicitly identify patients who may benefit from migraine surgery. This is confounded by significant between-study variation in the pre-intervention workup: for example, a proportion of studies used a positive response to botulinum toxin as part of the eligibility criteria, whereas others did not.[@bib0024], [@bib0029], [@bib0043]^--^[@bib0046], [@bib0048], [@bib0050], [@bib0053] Similarly, surgical intervention for migraine is assumed to be appropriate only for treatment-refractory cases (i.e. in those patients who fail to respond to multimodal best medical therapy or non-invasive options). However, most studies do not report on previous medication use or length of migraine history.[@bib0019], [@bib0025], [@bib0027], [@bib0028], [@bib0044]^--^[@bib0046], [@bib0048]^--^[@bib0052] A number of studies failed to report on adverse outcomes, raising the possibility of selective outcome reporting.[@bib0024], [@bib0028], [@bib0029], [@bib0043]^--^[@bib0046], [@bib0050], [@bib0051], [@bib0053] In general, recent studies have typically used nerve decompression approaches -- it is unclear as to what extent this is comparable with older studies using alternative surgical interventions (e.g. superficial temporal artery excision or cervical sympathectomy).[@bib0024], [@bib0053]

The three randomised controlled trials (RCTs) were assessed according to GRADE standards with additional consideration given to CONSORT Statement guidelines.[@bib0034], [@bib0054] One of these trials failed to report complete baseline data.[@bib0025], [@bib0027] Another study using a side-specific randomisation protocol failed to account for correlation in their data set and appeared to apply contradictory statistical tests.[@bib0028] Two RCTs did not adequately describe their patient enrolment criteria or randomisation methodology.[@bib0028], [@bib0051] In the two studies, where a surgical treatment arm was compared with a no-intervention control arm, statistically significant improvements were also noted in the control group, raising the possibility of regression to the mean.[@bib0025], [@bib0051]

Migraine headache outcomes {#sec0014}
--------------------------

Outcome reporting was variable, although pre- and post-operative migraine intensity, frequency, duration and MHI scores were relatively consistently reported. In general, surgical intervention improved scores across these outcomes. Migraine intensity, as measured on a visual analogue scale (range 0--10), was reported in 13 studies and improved from a pooled average of 8.0 to 3.9 following surgical intervention ([Table 4](#tbl0004){ref-type="table"}).Table 4Migraine intensity.Table 4Primary author & yearBaseline migraine intensityPost-intervention migraine intensityVAS scoreSDVAS scoreSDKnight 1962----50% experienced less intense MH symptoms[⁎⁎](#tb4fn2){ref-type="table-fn"}--Rapidis 1976----87.5% experienced complete resolution of MH symptoms[⁎⁎](#tb4fn2){ref-type="table-fn"}--Behin 20047.81.53.63.7Dirnberger 2004----63% experienced reduction or resolution of MH symptoms[⁎⁎](#tb4fn2){ref-type="table-fn"}--Poggi 20088.07.96.04.8Ducic 20097.91.41.91.8Guyuron 2005[\*](#tb4fn1){ref-type="table-fn"}8.51.24.53.2Guyuron 2011[\*](#tb4fn1){ref-type="table-fn"}Janis 20117.32.13.32.5Chepla 20128.30.25.00.3Chmielewski 20138.02.94.73.18.21.94.13.7Lee 20138.0--4.6--8.3--4.5--Gferer 20149.21.03.33.3Guyuron 20156.80.32.60.87.00.32.90.8Lin 20158.21.82.72.5Edoardo 2015--------Omranifard 20168.30.34.10.2Ascha 2017--------[^13][^14][^15][^16][^17][^18][^19]

Migraine frequency was measured in 11 studies and reduced from an average of 15.6 migraine headaches per month to 5.1 ([Table 5](#tbl0005){ref-type="table"}).Table 5Migraine frequency.Table 5Primary author & yearBaseline migraine frequencyPost-intervention migraine frequencyMH/monthSDMH/monthSDKnight 1962\>5------Rapidis 1976--------Behin 200417.711.27.77.6Dirnberger 200445% \>15, 40% 5--14, 15% 1--4[⁎⁎](#tb5fn2){ref-type="table-fn"}--58.4% experienced \>50% headache per day reduction[⁎⁎](#tb5fn2){ref-type="table-fn"}--Poggi 200811.99.31.32.9Ducic 2009--------Guyuron 2005[\*](#tb5fn1){ref-type="table-fn"}10.97.545.3Guyuron 2011[\*](#tb5fn1){ref-type="table-fn"}Janis 201116.511.13.86.5Chepla 201213.90.95.90.8Chmielewski 201319.38.49.99.814.69.45.17.6Lee 201318.1--7.2--16.1--7.1--Gferer 201418.510.43.76Guyuron 201514.21.81.90.714.61.82.20.8Lin 2015--------Edoardo 2015\>15------Omranifard 201615.93.36.42.3Ascha 2017--------[^20][^21][^22][^23][^24][^25]

Migraine duration (days) was reported in eight studies, with an average pre-operative duration of 0.9 and an average post-operative duration of 0.4 ([Table 6](#tbl0006){ref-type="table"}).Table 6Migraine duration.Table 6Primary author & yearBaseline migraine durationPost-intervention migraine durationDaysSDDaysSDKnight 1962--------Rapidis 1976--------Behin 2004--------Dirnberger 2004--------Poggi 200850% \<24 h, 44% 2 h--1 wk, 6% \>1 wk[⁎⁎](#tb6fn2){ref-type="table-fn"}------Ducic 2009--------Guyuron 2005[\*](#tb6fn1){ref-type="table-fn"}1.41.40.30.9Guyuron 2011[\*](#tb6fn1){ref-type="table-fn"}Janis 201110.90.50.4Chepla 20121.10.10.40.5Chmielewski 20130.70.70.40.71.21.40.40.9Lee 20130.9--0.5--1.1--0.5--Gferer 20140.70.50.20.4Guyuron 20150.40.10.20.040.40.10.10.04Lin 2015--------Edoardo 2015--------Omranifard 20161.10.50.50.3Ascha 2017--------[^26][^27][^28][^29][^30][^31][^32][^33]

Eight studies calculated a composite migraine headache index (MHI) by multiplying frequency, intensity and duration scores; this improved from a pooled average of 115.2 preoperatively to 14.5 post-operatively ([Table 7](#tbl0007){ref-type="table"}).Table 7Migraine headache index scores.Table 7Primary author & yearBaseline MHIPost-intervetion MHIScoreSDScoreSDKnight 1962--------Rapidis 1976--------Behin 2004--------Dirnberger 2004--------Poggi 2008--------Ducic 2009287.014.924.011.8Guyuron 2005[\*](#tb7fn1){ref-type="table-fn"}90.380.111.429.9Guyuron 2011[\*](#tb7fn1){ref-type="table-fn"}Janis 2011106.689.710.328.2Chepla 2012114.013.318.83.6Chmielewski 2013----------------Lee 2013130.3--25.6--107.7--27.4--Gferer 201499.495.710.118.0Guyuron 201541.09.62.50.942.09.52.90.9Lin 2015--------Edoardo 2015--------Omranifard 2016134.041.711.89.0Ascha 2017111.8--45.4--[^34][^35][^36][^37]

Adverse outcomes and recurrence rates {#sec0015}
-------------------------------------

Only 10 of the 18 included studies commented on adverse events ([Table 8](#tbl0008){ref-type="table"}).Table 8Recurrence of migraine and adverse outcomes.Table 8Primary author & yearIncomplete MH elimination[\*](#tb8fn1){ref-type="table-fn"} (% of patients)\>50% Reduction in MHI (% of patients)Adverse outcomes (% of patients)Adverse outcomes (type)Knight 1962--------Rapidis 197613------Behin 2004--------Dirnberger 200472------Poggi 200883--28Itching, numbness, alopecia, asymmetric brow elevation, corrugator muscle contraction, ptosis, frontalis contractureDucic 200957811Incisional cellulitisGuyuron 2005[⁎⁎](#tb8fn2){ref-type="table-fn"}758813Nerve injury, neck stiffness/weakness, numbness, altered sensation, haematomaGuyuron 2011[⁎⁎](#tb8fn2){ref-type="table-fn"}Janis 2011927138Haematoma, paraesthesia, alopecia, altered sensationChepla 2012--------Chmielewski 20136280----3691----Lee 20137480----7181----Gferer 2014499111Numbness, itchingGuyuron 201542950--47840--Lin 2015--------Edoardo 201561--0--Omranifard 201636760--Ascha 2017488225Neck discomfort, itching, altered sensation, hypertrophic scar, dehiscence[^38][^39][^40][^41][^42][^43]

Of these, seven described variable rates of post-operative complications and three studies reported no adverse events. The overall rate of adverse events was 11.6%, ranging from 0 to 38%. In the 14 studies, where complete elimination of migraine headache was reported, the average percentage of patients with recurrence of migraine following surgery was 57% (range 13--92%). No studies reported complete migraine elimination in all patients following surgery. A greater than 50% reduction in the MHI score was a commonly reported indicator of surgery success; in the 10 studies where this was reported, an average of 83.3% of participants achieved this threshold (range 71--95%).

Quality of life outcome measures {#sec0016}
--------------------------------

Assessment of additional generic and/or disease-specific patient-reported outcome measures was beyond the scope of this review. However, only 5 included studies reported on patient outcomes not directly related to the surgical intervention.[@bib0019], [@bib0025], [@bib0027], [@bib0046], [@bib0047], [@bib0052] One study reported statistically significant improvements using a previously validated migraine-specific disability assessment tool.[@bib0025], [@bib0027] The remaining four studies described qualitative benefits using non-validated questionnaires.[@bib0019], [@bib0046], [@bib0047], [@bib0052] No included study used a generic quality of life or depression tool. Where reported, migraine surgery appears to be associated with quality of life improvements, although these findings must be interpreted in the context of the quality of evidence provided.

Discussion {#sec0017}
==========

This paper describes the first PRISMA-compliant systematic review of surgical intervention for chronic migraine. It provides a descriptive, critical synthesis of the literature with particular attention to migraine-specific outcome measures and adverse event rates. Overall, our review suggests that surgical trigger site deactivation leads to symptomatic benefits in appropriately selected patients with chronic migraine, in that across all included studies, a positive intervention effect was observed. Nonetheless, flawed research methodology throughout the literature prevents this review from definitively supporting or refuting the hypothesis that surgical intervention is effective for chronic migraine.

All included studies reported an improvement in post-operative migraine intensity, with an average reduction of nearly 50% -- a figure consistent with that given in the three included RCTs. Similar improvements were seen across other disease-specific endpoints including migraine duration, frequency and composite headache scores, although this should be interpreted in the context of the benefits of placebo as seen in the PREEMPT trials.[@bib0013], [@bib0014], [@bib0015], [@bib0016]

Fourteen of the included studies were based on observational data. Significant methodological flaws in nine of these studies meant that their evidence quality assessment was downgraded to 'very low' according to GRADE criteria. Despite using a randomised trial design, the three prospective clinical trials did not provide enough reliable data to allow us to conclusively achieve our second and third review objectives, largely owing to flaws in trial methodology and intervention heterogeneity. For example, Guyuron et al. randomised patients to a complex intervention (including facial muscle resection, cranial nerve excision and/or nasal surgery -- where each patient received a different combination based on trigger sites) versus no intervention.[@bib0025], [@bib0027] Each participant in the treatment group therefore received an essentially different intervention, furthering the intra-group heterogeneity. A number of other methodological flaws in the trial design are detailed in [Table 2](#tbl0002){ref-type="table"}. The second RCT, also conducted by Guyuron et al. was a quasi-randomised trial where the same patient received one treatment on one hemi-cranium and the alternative intervention on the opposite side.[@bib0028] There are issues with this trial design, including difficulties when interpreting results and the importance of the unit of analysis.[@bib0055] Similar issues were encountered in the third RCT: here, Omranifard et al. evaluated a complex intervention versus non-standardised medical therapy, again reducing the reliability of the observed effects due to intra- and inter-group heterogeneity.[@bib0051] These issues meant that the quality of evidence provided by these RCTs was downgraded to low, using the GRADE approach.

Adverse event reporting was inconsistent and ranged from 0% to 38% in 10 studies. Inconsistent adverse event reporting complicates interpreting this variability; indeed, the other seven studies did not report on adverse events at all. Such inconsistency is concerning, particularly when considering the proposed benefits of migraine surgery versus botulinum toxin regimens, which has consistently low rates of adverse events. This must be considered a standard outcome in future research on migraine surgery.

Extracranial migraine trigger site deactivation is based on the theoretical mechanism that surgical intervention is able to make permanent the temporary effects of botulinum toxin. This is the rationale for our evaluation of the 'permanence' of the surgical intervention, in terms of both migraine recurrence and complete elimination. Interestingly, there was a pooled average of 60% of study participants who had recurrence of migraine after surgical intervention -- i.e., only 40% of patients who underwent surgical intervention achieved permanent symptomatic relief. In one paper, 92% of patients had recurrence of symptoms following multiple trigger site deactivation.[@bib0019] This was also seen in a similar study involving multiple trigger site deactivation, where an 83% recurrence rate was observed.[@bib0052] Only in four studies was the rate of recurrence less than 50% during the follow-up period.[@bib0028], [@bib0049], [@bib0051], [@bib0053] However, some consider migraine to be a largely genetically determined disorder of brain biology that cannot be cured, and therefore, modulatory interventions are required. Considering this concept, the recurrence of symptoms may be unavoidable.

In contrast to the high rates of migraine recurrence, all studies reported symptomatic improvement, with a pooled average of 83% of study participants achieving a greater than 50% reduction in MHI scores. The migraine headache index (MHI) is a widely used tool that combines migraine duration, migraine intensity and migraine frequency to generate a composite outcome. The MHI was initially developed to ensure compatibility of outcome measures between studies, including key migraine-specific variables of interest. However, MHI scores from separate studies are very difficult to compare statistically because of differences in the collection of baseline data and the inherent variability of each component of the MHI. In addition, extrinsic factors affecting one or more of these subjectively assessed components are not accounted for. For example, if a patient used an abortive medication, reducing the duration of the migraine attack, but not affecting its frequency or severity, there will be an unrepresentative change in the overall MHI. This may act as a confounding factor when measuring the effect of surgical intervention. The authors feel that the individual components of the MHI, along with more objective measures of intervention effect, are best employed in the migraine population.

Despite the methodological issues already described, the consistent improvement in migraine-related outcomes demonstrates that, while surgery may not achieve permanence of the 'Botox effect', it may be associated with symptomatic improvement for a period of time. The actual difference in effectiveness at improving symptoms between botulinum toxin alone versus surgery remains to be proven in an adequately powered clinical trial.[@bib0056] Of note, of the 15 studies using an extracranial nerve deactivation strategy, only nine employed preoperative response to botulinum toxin or local anaesthetic as part of their trigger site identification algorithm.

This systematic review draws two key conclusions: 1. There is insubstantial evidence supporting the effectiveness of surgical intervention for chronic migraine primarily due to flaws; 2. An analysis of the current primary clinical research data suggests that surgical intervention may benefit appropriately selected chronic migraine patients. Considering these findings, the authors believe that an adequately powered, randomised clinical trial of a well-defined surgical intervention for migraine compared to botulinum toxin and/or placebo is needed. It should include a variety of outcome measures including objective measures of effect, validated generic and migraine-specific patient-reported outcome measures and comprehensive reporting of adverse event and recurrence rates. Follow-up will need to be of sufficient length to compare the longevity of surgical intervention versus botulinum toxin. This proposed trial could provide definitive evidence for clinicians and patients alike, ensuring best practice and fully informed consent.

Strengths and limitations {#sec0018}
-------------------------

This systematic review is the first PRISMA-compliant, prospectively registered, critical assessment of the evidence base for migraine surgery. Throughout, we have focused on sound systematic review methodology to present an unbiased and scientific assessment of the body of knowledge for migraine surgery. Our search strategy included a broad range of study types to capture all relevant reports of primary clinical research, enabling a global evaluation of the topic. Although we were unable to perform statistical meta-analysis, our descriptive analysis allows an overview of the likely effect of a variety of surgical interventions, with a snapshot of the rates of recurrence and adverse events. This review also identifies specific flaws that have affected the reliability of migraine surgery research to date, with a view to providing direction towards definitive, clinically meaningful research.

This review was limited by a paucity of methodological quality in included studies, heterogeneous interventions and inconsistent outcome reporting. Variability in baseline data, intervention data and outcome data precluded formal meta-analysis. The authors of 7 studies eligible for inclusion were contacted with requests for additional data to enable data extraction. The data requested from these 7 studies included baseline demographics, preoperative migraine data and post-operative outcome data. Unfortunately, none of the authors of these papers were able to provide data, which significantly reduced our final cohort of included studies. These limitations prevent the authors from providing definitive clinical recommendations either for or against migraine surgery, based on the current evidence.

Conclusion {#sec0019}
==========

The current literature supporting surgical intervention for chronic migraine is insufficient to provide reliable guidance for clinicians. All 18 of the studies included in our review suggest a beneficial effect of surgical intervention for migraine in selected patients; however, methodological flaws throughout the literature reduce the reliability of these findings. According to the GRADE approach, we cannot definitively state that surgery for migraine is effective for relief of symptoms. Migraine surgery is an evolving field and future research should build on deficiencies in the current literature. A definitive, multicentre trial of migraine surgery will provide substantive evidence to guide patients and clinicians.
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[^1]: SD - standard deviation.

[^2]: ICHD - International Classification of Headache Disorders.

[^3]: IHS - International Headache Society guidelines (exact criteria not specified).

[^4]: U/L - unilateral.

[^5]: B/L - bilateral.

[^6]: ENT - ear, nose and throat surgeon.

[^7]: LA - local anaesthetic.

[^8]: CT - computed tomography scan.

[^9]: Blank cells (-) indicate not specified by authors.

[^10]: Diagnostic criteria provided in as much detail as specified in paper -- e.g., specific ICHD criteria vs IHS guidelines vs unspecified.

[^11]: Clinician diagnosing chronic migraine.

[^12]: Number of discrete surgical sites listed per side; e.g., 1--4 (B/L) indicates one-to-four sites per hemicranium (i.e., between two and eight total operative sites); U/L indicates surgery on one side only.

[^13]: MH - migraine headache.

[^14]: SD - standard deviation.

[^15]: VAS - visual analogue scale, scored 0--10, where higher numbers indicate more severe symptoms.

[^16]: Blank cells (-) indicate data not collected by authors.

[^17]: All scores given to 1 dp (where appropriate).

[^18]: Migraine parameters provided at baseline and five-year follow-up.

[^19]: Detail as specified in paper.

[^20]: MH - migraine headache.

[^21]: SD - standard deviation.

[^22]: Blank cells (-) indicate data not collected by authors.

[^23]: All scores given to 1 dp (where appropriate).

[^24]: Migraine parameters provided at baseline and five-year follow-up.

[^25]: Detail as specified in paper.

[^26]: MH - migraine headache

[^27]: SD - standard deviation

[^28]: hr - hour

[^29]: wk - week

[^30]: Blank cells (-) indicate data not collected by authors

[^31]: All scores given to 1 dp (where appropriate)

[^32]: Migraine parameters provided at baseline and five-year follow-up.

[^33]: Detail as specified in paper.

[^34]: MHI - migraine headache index (calculated by frequency x intensity x duration).

[^35]: SD - standard deviation.

[^36]: All scores provided to 1 dp.

[^37]: MHI scores provided at baseline and five-year follow-up.

[^38]: MHI - migraine headache index.

[^39]: MH - migraine headache.

[^40]: Blank cells (-) indicate not reported by authors.

[^41]: All figures rounded to the nearest integer.

[^42]: Incomplete MH elimination defined as persistent migraine symptoms (i.e., \<100% relief).

[^43]: Data at five-year follow-up.
